API operations are no longer viewed only through the lens of cost and supply. In today’s environment of heightened regulatory scrutiny, complex development requirements, and fragile global supply chains, APIs have become central to business continuity, speed to market, and long term competitiveness.
In this conversation with Mr Naveen Kapil, Chief API Operations at Cipla, we explore how the perception of APIs has shifted from a transactional function to a strategic capability. Mr Kapil shares how data driven decision making, compliance readiness, and development aligned API strategies directly influence formulation timelines, regulatory confidence, and market access.
The discussion highlights how building strong technical capabilities, resilient supply architectures, and digitally enabled operations allows API organizations to move beyond reliability and become true partners in growth.
For a long time, APIs were largely discussed in terms of cost and availability. When you look at API operations today, what do you feel has genuinely changed in how their value is perceived?
Before the COVID era, APIs were largely evaluated through the lenses of cost and availability. Today, however, their importance is directly linked to strategic resilience and innovation. Modern API operations now focus on:
- Risk → Quantified P&L impact:
- Pharma companies lose significant profit due to supply chain disruptions. Without in house API capabilities, manufacturers are highly vulnerable to suppliers charging disproportionately high prices during shortages.
- Rising regulatory complexity limiting growth:
- In FY2023, the FDA issued around 500+ Form 483 observations to drug manufacturing sites. To maintain strong compliance and ensure continuous adherence to regulatory expectations, owning API facilities has become essential.
- Formulation speed driven by API development readiness:
- Increasingly stringent requirements, such as nitrosamine ready control strategies, have made API readiness a critical bottleneck. The FDA’s 2024/2025 updates formalized a three step mitigation framework (risk assessment, confirmatory testing, and required changes) along with CPCA potency categorization. API suppliers that pre establish these assessments can eliminate months of downstream delays.
For Cipla:
- Digital & Data-Tech Integration:
- We have embedded analytics and automation across operations to enhance productivity and quality, ensuring a stable and reliable supply for both captive use and external customers.
- Capability Building:
- Initiatives such as the DnA academies and Lean Six Sigma programs have become central to our operating model, shifting us from transactional supply chains to knowledge driven, high capability ecosystems.
- Compliance as a Differentiator:
- Regulatory compliance and audit readiness are now strategic advantages, shaping customer confidence and market positioning. Our periodic internal audits by the central quality team ensure that each plant remains continuously prepared for any regulatory inspection.
From your experience, when does an API operation stop being “just supply” and start influencing formulation timelines, filing confidence, and even market access decisions?
It crosses the threshold when it consistently influences downstream outcomes:
Formulation Timelines
A transparent communication channel between Formulation and API teams ensures delivery of the right-quality material at the right time, enabling concurrent formulation readiness.
Providing a complete solid state package upfront, covering polymorph mapping, PSD control, hygroscopicity, flow and compressibility attributes, along with stable impurity profile data significantly reduces experimental iterations at the formulation stage, thereby accelerating filing timelines.
Filing Confidence
A well maintained lifecycle DMF, supported by proactive change management practices, including annual updates, risk prioritized post approval changes, and validated alternate synthetic routes, greatly reduces regulatory risk and strengthens submission confidence.
Cipla-Specific Points
- Continuous Manufacturing and Flow Chemistry shorten cycle times, directly enabling faster formulation readiness.
- Integrated Planning Systems (SAP IBP, PPDS) tightly align API production plans with formulation and filing milestones, improving predictability.
- Regulatory Confidence: APIs with strong compliance track records speed up dossier approvals, ultimately influencing launch timelines and enabling earlier market entry.
Across the industry, data often shows that a small percentage of APIs account for a disproportionate share of supply disruptions or regulatory observations. How should API leaders use this insight to prioritise investments?
To adopt a risk weighted portfolio framework anchored on a clear, transparent metric:
API Criticality Score (ACS) ACS = (Revenue at Risk in Formulation × Launch/Tender Sensitivity) × (Supply Fragility × Regulatory Exposure)
Prioritization Approach
- Tier 1 (Top 10–15 APIs by ACS):
Prioritize significant investments, route diversification, second site qualification, inventory buffers, SPC, PAT deployment, and strengthened lifecycle DMFs.
- Tier 2:
Drive targeted process robustness initiatives such as refreshed DoE studies, impurity pathway mapping, and enhanced supplier quality assurance.
- Tier 3:
Use commercial levers (contracts, pricing structures) with minimal capital investment.
Cipla-Specific Direction
- Risk-Based Investment Focus:
Prioritize molecules with high disruption risk or frequent regulatory observations for capacity augmentation and alternate vendor development.
- Capex Allocation:
Channel capital proposals, such as kilo labs and new manufacturing blocks, towards APIs most critical for business continuity.
Many customers talk about partnership but still negotiate aggressively on price. In practice, what makes a customer treat an API manufacturer as a long-term partner rather than re-benchmarking them periodically?
Beyond price negotiations, partnership solidifies when manufacturers:
- Shared risk & value models:
- Launch-aligned pricing (ramp pricing or milestone rebates) and availability SLAs (OTIF with service credits).
- Volume corridors with material visibility (12–18 month rolling forecasts) reduce firefighting and price re-benchmarking cycles.
- Technical intimacy:
- Joint control strategy: co-authored impurity risk files, agreed specs with change governance.
- Lifecycle support:
- Proactive DMF amendments, nitrosamine risk updates, and post-approval change playbooks aligned to the sponsor’s filing calendar.
- Inspection readiness shared (mock audits, data integrity health scores).
Reliability demonstrated, not promised:
At Cipla:
- Offer Technical Co-Development: Joint work on formulation compatibility and stability studies.
- Ensure Supply Reliability: OTIF (On-Time-In-Full) metrics >90% and proactive risk mitigation build trust.
- Provide Transparency: Sharing compliance dashboards and audit readiness fosters confidence.
There is a common belief that stronger quality and compliance always come at a higher cost. From an operations standpoint, where does this assumption break down?
Quality and compliance lower the total cost of operations when they systematically reduce waste, variability, and rework:
- Right‑First‑Time (RFT) & Yield
- Robust control strategies and the use of PAT improve yields and cut batch failures. The resulting COGS reduction significantly outweighs the incremental QA operating expense.
- Deviation & Investigation Load
- Fewer deviations translate into reduced analyst effort, shorter batch hold times, and lower scrap, directly improving productivity and cost efficiency.
- Tech Transfer Efficiency
- Comprehensive knowledge packages, including fate‑and‑purge data, defined critical parameter ranges, and clear scale‑up envelopes, accelerate validation and reduce the number of batches required for PPQ.
At Cipla
- Automation & Digitalization:
Reduce manual intervention, minimize errors, and decrease rework, directly lowering operational costs. - Lean Six Sigma Programs:
Drive yield improvements and waste reduction without increasing overhead. - Continuous Improvement Programs (CIP/AVD):
Strengthen compliance while simultaneously enhancing cost efficiency and operational performance.
Looking ahead, what two or three capabilities must API organisations deliberately build if they want to be seen as strategic partners rather than transactional vendors?
- Development Readiness & Technical Operations Excellence
- Standardized delivery of solid‑state data and formulation‑enabling analytical packages.
- Strong lifecycle DMF management supported by proactive regulatory intelligence.
- Advanced impurity science, including fate‑and‑purge modeling and comprehensive nitrosamine risk assessments.
- Resilient Supply Architecture
- Dual‑route and dual‑site manufacturing strategies for Tier‑1 APIs, with qualified alternates for critical precursors.
- Network planning that uses buffers calibrated to demand variability and supply‑chain lead times.
- Integrated supplier‑quality systems through joint audits, shared CAPA frameworks, and raw‑material risk scoring mechanisms.
- Customer Co‑Creation & Commercial Design
- Collaborative, risk‑sharing commercial models: availability SLAs, launch‑linked pricing structures, and transparent data‑sharing terms.
- Quarterly business reviews anchored in operational KPIs such as OTIF, RFT, yield, deviation density, and inspection performance.
- Joint change‑control governance incorporating structured impact assessments and comparability protocols.
- Integrated forecasting and S&OP alignment to minimize variability and mitigate pricing pressures.
Critical Capabilities Stand Out
- Next‑Generation Manufacturing Technologies:
Deployment of continuous production platforms, SCADA/DCS systems, and advanced analytics for real‑time performance visibility. - Digital‑Native Organization:
Building teams equipped for data‑driven decision‑making and modern operational workflows.
To hear these leaders speak directly on the insights, realities, and evolving trends shaping API manufacturing, readers can engage with the discussion live at API Connect 2026, organised by Ki Eventz, on 22 January 2026 at The Belvedere Golf & Country Club, Ahmedabad.
Disclaimer: The views and opinions expressed in this editorial are those of the interviewees and are based on their professional experience in pharmaceutical engineering and sterile manufacturing. They do not necessarily reflect the official views, policies, or positions of Hello Pharma, its management, or its affiliates. Hello Pharma does not endorse or take responsibility for any specific technical, commercial, or regulatory interpretations presented in this article. Readers are encouraged to independently evaluate the information shared, review applicable regulatory guidance, and rely on their own experience, expertise, and professional judgment before making decisions related to equipment selection, system design, validation strategy, or regulatory compliance.
